Breast Cancer Clinical Trial
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Summary
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
Full Description
In this study, the investigators propose that persistent disseminated tumor cells (DTC) present after systemic therapy represent a unique subpopulation of all DTC, are predictors of a poor response to systemic therapy and correlate with poor clinical outcome. The investigators hypothesize that systemic therapy-resistant DTC can be identified by their expression of a unique constellation of tumor marker proteins which may be similar to those expressed by breast cancer stem cells. In this research, the investigators' specific aims are : 1) to characterize tumor markers expressed by DTC which are present after systemic therapy, 2) to compare the expression of these markers to that on DTC detected prior to systemic therapy, 3) to correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence, 4) to utilize biomarkers identified in Specific Aims 1 and 2 to isolate purified DTC for further molecular analysis.
Eligibility Criteria
Inclusion Criteria:
Recently diagnosed with clinical stage II, III, or IV breast cancer
Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have already completed neoadjuvant systemic therapy are also eligible
Must be >= 18 years of age
If female, must not be pregnant
Must not have Hepatitis B, C, or HIV
Must be willing and able to sign informed consent document
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Saint Louis Missouri, 63119, United States More Info
Principal Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
Sub-Investigator
How clear is this clinincal trial information?